-

STAAR Surgical to Participate in Upcoming Investor Conferences

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that management will participate in several upcoming investor conferences. The Company has issued an updated investor presentation it will use during the upcoming meetings, which is available on the Company’s investor website at investors.staar.com.

Caren Mason, President & CEO, and Patrick F. Williams, CFO, will participate in the following investor conferences during the month of September:

  • William Blair West Coast Field Trip 2020, Wednesday, September 2
  • Wells Fargo 2020 Virtual Healthcare Conference, Wednesday, September 9
  • Morgan Stanley 18th Annual Global Healthcare Conference, Monday, September 14
  • Sidoti & Co. Small Cap Virtual Investor Conference, Thursday, September 24

Attendance at the investor conferences is by invitation only from each sponsoring research brokerage firm. Please contact the brokerage firm directly for more information.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

Contacts

Investors & Media
Brian Moore
Vice President, Investor, Media Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com

STAAR Surgical Company

NASDAQ:STAA

Release Versions

Contacts

Investors & Media
Brian Moore
Vice President, Investor, Media Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com

More News From STAAR Surgical Company

STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended April 3, 2026. First Quarter 2026 Financial Overview Net sales of $93.5 million, up 119.6% Y/Y Net sales excluding China of $46.1 million, up 6.0% Y/Y Gross margin at 73.6% vs. 65.8% a year ago Net income of $5.2 million or $0.10 per diluted share, com...

STAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results in combination with a shareholder letter for the first quarter ended April 3, 2026, on Wednesday, May 13, 2026, after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and bus...

STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for the first quarter ended April 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement because it expects to be interacting with members of the investment community, as well as with surgeons and other members of t...
Back to Newsroom